Skip to content
EHP Banner Ad

Environmental Health Perspectives

Facebook Page EHP Twitter Feed Open Access icon  

Research December 2017 | Volume 125 | Issue 12

Email this to someoneShare on FacebookTweet about this on TwitterShare on LinkedInShare on Google+Share on StumbleUpon
Environ Health Perspect; DOI:10.1289/EHP2062

Urine Arsenic and Arsenic Metabolites in U.S. Adults and Biomarkers of Inflammation, Oxidative Stress, and Endothelial Dysfunction: A Cross-Sectional Study

Shohreh F. Farzan,1* Caitlin G. Howe,1* Michael S. Zens,2 Thomas Palys,3 Jacqueline Y. Channon,4,5 Zhigang Li,6 Yu Chen,7 and Margaret R. Karagas2
Author Affiliations open

1Department of Preventive Medicine, Keck School of Medicine of University of Southern California, Los Angeles, California, USA

2Department of Epidemiology, Dartmouth Geisel School of Medicine, Dartmouth College, Lebanon, New Hampshire, USA

3Center for Molecular Epidemiology at Dartmouth, Dartmouth Geisel School of Medicine, Dartmouth College, Lebanon, New Hampshire, USA

4Department of Microbiology and Immunology and Norris Cotton Cancer Center, Dartmouth Geisel School of Medicine, Dartmouth College, Lebanon, New Hampshire, USA

5Norris Cotton Cancer Center, Dartmouth–Hitchcock Medical Center, Dartmouth Geisel School of Medicine, Dartmouth College, Lebanon, New Hampshire, USA

6Department of Biomedical Data Science, Dartmouth Geisel School of Medicine, Dartmouth College, Lebanon, New Hampshire, USA

7Department of Population Health, New York University School of Medicine, New York, New York, USA

PDF icon PDF Version (244 KB)

  • Background:
    Arsenic (As) exposure has been associated with increased risk for cardiovascular disease (CVD) and with biomarkers of potential CVD risk and inflammatory processes. However, few studies have evaluated the effects of As on such biomarkers in U.S. populations, which are typically exposed to low to moderate As concentrations.
    We investigated associations between As exposures and biomarkers relevant to inflammation, oxidative stress, and CVD risk in a subset of participants from the New Hampshire Health Study, a population with low to moderate As exposure (n=418).
    Associations between toenail As, total urine As (uAs), and %uAs metabolites [monomethyl (%uMMAV), dimethyl (%uDMAV), and inorganic (%iAs) species] and plasma biomarkers, including soluble plasma vascular and cellular adhesion molecules (VCAM-1 and ICAM-1, respectively), matrix metalloproteinase-9 (MMP-9), tumor necrosis factorα, plasminogen activator inhibitor-1 (PAI-1), and urinary oxidative stress marker 15F2tisoprostane (15F2tIsoP), were evaluated using linear regression models.
    Covariate-adjusted estimates of associations with a doubling of urinary As suggested an 8.8% increase in 15F2tIsoP (95% CI: 3.2, 14.7), and a doubling of toenail As was associated with a 1.7% increase in VCAM-1 (95% CI: 0.2, 3.2). Additionally, a 5% increase in %uMMA was associated with a 7.9% increase in 15F2tIsoP (95% CI: 2.1, 14.1), and a 5% increase in %uDMA was associated with a 2.98% decrease in 15F2tIsoP [(95% CI: 6.1, 0.21); p=0.07]. However, in contrast with expectations, a doubling of toenail As was associated with a 2.3% decrease (95% CI: 4.3, 0.3) in MMP-9, and a 5% increase in %uMMA was associated with a 7.7% decrease (95% CI: 12.6, 2.5) in PAI-1.
    In a cross-sectional study of U.S. adults, we observed some positive associations of uAs and toenail As concentrations with biomarkers potentially relevant to CVD pathogenesis and inflammation, and evidence of a higher capacity to metabolize inorganic As was negatively associated with a marker of oxidative stress.
  • Received: 14 April 2017
    Revised: 13 November 2017
    Accepted: 15 November 2017
    Published: 15 December 2017

    Address correspondence to S.F. Farzan, 2001 N. Soto St., Los Angeles, CA, 90032. Telephone: (323)-442-5101; Email:

    Supplemental Material is available online (

    These authors contributed equally to this work.

    The authors declare they have no actual or potential competing financial interests.

    Note to readers with disabilities: EHP strives to ensure that all journal content is accessible to all readers. However, some figures and Supplemental Material published in EHP articles may not conform to 508 standards due to the complexity of the information being presented. If you need assistance accessing journal content, please contact Our staff will work with you to assess and meet your accessibility needs within 3 working days.

  • PDF icon Supplemental Material PDF (203 KB)

    Note to readers with disabilities: EHP has provided a 508-conformant table of contents summarizing the Supplemental Material for this article (see below) so readers with disabilities may determine whether they wish to access the full, nonconformant Supplemental Material. If you need assistance accessing journal content, please contact Our staff will work with you to assess and meet your accessibility needs within 3 working days.
    PDF icon Supplemental Table of Contents PDF (122 KB)


Worldwide, an estimated 200 million individuals are exposed to water arsenic (As) concentrations exceeding the 10-μg/L guideline set by the World Health Organization (WHO) (2011). Arsenic is an established human carcinogen that has also been associated with a growing number of noncancer outcomes (NRC 2013). In particular, chronic As exposure has been positively associated with cardiovascular disease (CVD) (Farzan et al. 2015a; James et al. 2015; Moon et al. 2013; reviewed in NRC 2013; Moon et al. 2012). Although the majority of research on As and CVD has been conducted in populations exposed to relatively high As levels, such as in Bangladesh, where concentrations typically exceed the country’s national drinking-water standard of 50 μg/L, recent evidence suggests that low to moderate As exposure may be associated with CVD-related morbidity (Gong and O’Bryant 2012; James et al. 2015; Monrad et al. 2017; Moon et al. 2013; Mordukhovich et al. 2009) and mortality (D’Ippoliti et al. 2015; Farzan et al. 2015a; Medrano et al. 2010).

Arsenic-induced CVD may be mediated by increased inflammation and oxidative stress, which adversely affect vascular endothelial function. This inference has been supported by both experimental and epidemiological studies (Burgess et al. 2013; Chen et al. 2007; Engström et al. 2010; Kurzius-Spencer et al. 2016; Lemaire et al. 2015; Ma et al. 2012; Mo et al. 2011; Soucy et al. 2005; Wu et al. 2012, 2014). However, the majority of existing studies utilized high doses of As or evaluated populations exposed to relatively high As concentrations, such as populations in Bangladesh (Chen et al. 2007; Wu et al. 2012). In the United States, most water As concentrations typically fall in the low to moderate range, but higher levels of contamination (>100 μg/L) have been documented, including in parts of Maine and New Hampshire (Flanagan et al. 2014; USGS 2010). In New Hampshire, 40% of households depend on private wells, and >10% of these wells contain water As concentrations >10 μg/L (Karagas et al. 1998).

We previously reported that low to moderate As exposure is associated with increased CVD-related mortality among long-term smokers in the New Hampshire Health Study (NHHS) (Farzan et al. 2015a). The goal of the present project was to evaluate whether As exposure is associated with biomarkers of inflammatory processes, endothelial dysfunction, and oxidative stress that may reflect pathogenic mechanisms relevant to CVD (Mozos et al. 2017; Poredoš and Ježovnik 2015), including plasma matrix metalloproteinase-9 (MMP-9), tumor necrosis factor-α (TNF-α), plasminogen activator inhibitor-1 (PAI-1), soluble vascular and intercellular adhesion molecules (VCAM-1 and ICAM-1, respectively), and urinary 15-F2t-isoprostane (15-F2t-IsoP), which to our knowledge has not been evaluated previously in relation to As exposure, in the NHHS. We also evaluated whether the percentages of uAs metabolites are differentially associated with these biomarkers because a reduced capacity to fully metabolize inorganic As (iAs) has been associated with many As-related health outcomes (Steinmaus et al. 2010), including CVD (Chen et al. 2013b). Given the increasing evidence that susceptibility to As toxicity may differ by sex (NRC 2013), we also explored potential differences between men and women.



Participants in the present study were controls selected as part of a population-based case–control study of keratinocyte cancer in U.S. adults residing in New Hampshire (Gilbert-Diamond et al. 2013). Controls were randomly selected from population lists provided by a) the New Hampshire Department of Transportation for participants <65 y old and b) Medicaid and Medicare Services for participants ≥65 y old and frequency-matched to keratinocyte cancer case distribution on sex and age. Participants were eligible if they could speak English and had a listed phone number. All participants provided informed consent in accordance with the Committee for the Protection of Human Subjects at Dartmouth College. For the present study, biomarkers were measured in plasma (TNF-α, MMP-9, PAI-1, ICAM-1, VCAM-1) or urine (15-F2t-IsoP) samples from a subset of 418 control participants (78% of 535 total controls) from the most recent phase of the NHHS (September 2008 through June 2012) who had available plasma (n=396) or urine (n=418) samples (or both) for biomarker analysis, along with available measures of either toenail As (n=418) or urine As (n=403).

General Characteristics

Sociodemographic details, lifestyle factors, and other general characteristics, including age, education, marital status, tobacco smoke use, monthly alcohol consumption, and self-reported height and weight [used to calculate body mass index (BMI)], were determined by a structured in-person interview, which was typically conducted at the participant’s residence.

Water Arsenic

Tap-water samples were collected from participants’ homes and were tested at the Trace Element Analysis Core at Dartmouth College using inductively coupled plasma mass spectrometry (ICP-MS) with a quadrupole collision cell 7500c Octopole Reaction System ICP mass spectrometer (Agilent) and helium as a collision gas to remove polyatomic interferences, as described previously (Karagas et al. 2001). This method has a detection limit ranging from 0.001 to 0.04 μg/L, with <5% of all samples below the limit of detection. Samples with As concentrations below the limit of detection were set to (limit of detection/√2).

Toenail Collection and As Measures

Upon enrollment, participants were mailed instructions and materials for the collection of toenail clippings. Toenails were processed and As concentrations were measured at the Trace Element Analysis Core at Dartmouth College using ICP-MS, as described previously (Davis et al. 2014). This method has a detection limit ranging from 0.02 to 1.23 μg/g, with 9% of samples below the limit of detection. Samples with As concentrations below the limit of detection were set to (limit of detection/√2). Toenail As levels were available for all 418 participants.

Urine Collection

Urine-collection kits with instructions and materials necessary to collect first-morning-void urine samples were mailed to participants, who were instructed to refrigerate the urine samples until interviewers collected it later that day. Urine samples were aliquoted and frozen at −80°C within 24 h of collection and were shipped on dry ice to the University of Arizona for urine As analyses.

Urine As and %As Metabolites

Urine As was measured using a high-performance liquid chromatography (HPLC) ICP-MS system, as described previously (Gilbert-Diamond et al. 2011). This As speciation method quantifies the concentration of iAs species (iAsIII and iAsV) and organic As species (MMAV, DMAV, and arsenobetaine). This method had detection limits ranging between 0.03 and 0.30 μg/L for individual metabolites, with 0%, 4.8%, and 28.9% of the study population below the detection limit for DMA, MMA, and iAs, respectively. All samples had detectable levels of at least one metabolite after exclusion of arsenobetaine. Total urinary As (uAs) was calculated as the sum of iAsIII, iAsV, MMAV, and DMAV and was adjusted for specific gravity. The proportion of iAs in urine (%uiAs) was calculated as [iAsIII+iAsV/(uAs)]×100. The proportion of MMA in urine (%uMMA) and the proportion of DMA in urine (%uDMA) were calculated as follows: [(MMA/uAs)×100] and [(DMA/uAS)×100], respectively. Any As metabolite concentrations below the limit of detection were set to (limit of detection/√2), before calculating uAs or proportions of metabolites in urine. Urine As measures were available for n=403 of the 418 total participants.

Blood Collection

Venous blood samples of 20–30 mL were collected in heparinized tubes as described previously (Karagas et al. 1999, 2006) at the time of the interview and were available for analysis for n=396 of the 418 total participants. Blood was separated by centrifugation at 2,500×g for 20 min at 4°C, and each component (plasma, red blood cells, buffy coat) was labeled and stored separately at −80°C until analysis.

Markers of Inflammation and Endothelial Function

Plasma biomarkers were measured at the DartLab (Geisel School of Medicine at Dartmouth, Hanover, NH). Briefly, ICAM-1, MMP-9, TNF-α, and VCAM-1 were measured using the Meso Scale Discovery (MSD) multispot assay system with V-PLEX or Ultra-Sensitive kits (Dabitao et al. 2011) according to the manufacturer’s instructions. Standards and spikes were measured in triplicate, and samples were measured once. Plates were read on a Sector Imager 2400. MSD Discovery Workbench analysis software with 4-parameter logistic curve-fitting was used for data analysis. PAI-1 was also measured in plasma at the DartLab, using a MILLIPLEX-MAP® human magnetic bead platform (EMD Millipore) according to the manufacturer’s instructions and as described previously (Farzan et al. 2017).

Plasma samples were randomized across plates. Samples were diluted 1:1,000 for soluble ICAM-1 and VCAM-1, 1:10 for MMP-9, 1:400 for PAI-1, and were left undiluted for TNF-α. Assays were performed in six separate runs. Approximately 10% of sample wells on each plate were reserved for quality-control samples. Replicates of four different nonstudy plasma samples were included on each plate to account for inter- and intraplate variability; coefficients of variation for these five markers ranged from 7–23% and 5–21%, respectively. All assays were within the range of acceptable variability according to the manufacturer’s standards and are considered generally acceptable in epidemiological biomarker studies (Tworoger and Hankinson 2006). Three individuals had VCAM-1 and ICAM-1 levels that were below detection and were set to (limit of detection/√2). A portion of the samples tested for PAI-1 could not be reliably assessed (n=29) because their values fell above the range of the standard curve; therefore, these samples were excluded, resulting in a sample size of n=367 for PAI-1 analyses.

15-F2t-IsoP was measured in urine using a competitive enzyme-linked immunoassay kit (Oxford Biomedical Research) according to the manufacturer’s instructions. Before analysis, urine samples were incubated at 37°C for 2 h with β-glucuronidase to remove glucuronic acid conjugates on 15-F2t-IsoP for a more accurate assessment of total 15-F2t-IsoP. Duplicate samples in a 96-well plate were diluted 1:4 with buffer and were incubated with 15-F2t-IsoP horseradish peroxidase conjugate at room temperature for 2 h, then washed 3 times. 15-F2t-IsoP concentrations were determined by adding 3,3′,5,5′-tetramethylbenzidine (TMB) substrate and quantifying colorimetric readings at 450 nm against a standard curve. Readings from duplicates were averaged. Approximately 10% of wells were reserved for quality-control samples and reagent blanks. Replicates of a nonstudy composite urine sample were included on each plate to account for inter- and intraplate variability, which were 7.1% and 6.4%, respectively. 15-F2t-IsoP concentrations were analyzed in a total of 12 separate plates, completed over four separate runs.

Specific Gravity

Specific gravity (SG) was measured using an Atago Pocket Refractometer. Urine analytes (uAs and urinary 15-F2t-IsoP) were adjusted for SG using the following equation: [(SGMEAN–1)/(SGSAMPLE–1)]×(concentrations of analyteSAMPLE) (Duty et al. 2005). In models that simultaneously evaluated uAs and urinary 15-F2t-IsoP, these analytes were not adjusted for SG; instead, SG was included in the model as a covariate.

Statistical Analyses

Summary statistics were calculated for each variable [mean±SD for continuous variables and n (%) for categorical variables] in the whole study sample and separately by sex. To stabilize variances for parametric model assumptions and to reduce the influence of extreme values, transformations were applied to variables with skewed distributions. A natural log transformation [ln(X)] was applied to the following variables to normalize their distributions: uAs, toenail As, BMI, VCAM-1, ICAM-1, MMP-9, TNF-α, PAI-1, and 15-F2t-IsoP. Arsenic metabolite variables %uiAs, %uMMA, and %uDMA were left untransformed to facilitate the interpretation of results. Level of educational attainment, marital status, and age were categorized as binary variables (at least college educated vs. less than college educated, married vs. not married, and ≥65 y old vs. <65 y old, respectively). Cigarette smoking status was categorized into three levels: never smoker (reference group), former smoker, and current smoker. Alcohol consumption was categorized into four levels: never drinker (reference group), former drinker, current light drinker (≤median 336 g/month) and current heavy drinker (>median 336 g/month). Fish consumption information was derived from a semiquantitative, self-administered food-frequency questionnaire conducted at the time of the interview and was defined as consuming some type of fish product (tuna, dark fish, other fish, breaded fish, or shrimp) ≥1 time per month. Batch assignment, to control for batch-to-batch variability, was included as a dummy variable by coding n−1 dummy variables for the number of lab batches for the respective marker (batch 1=reference group). The number of batches differs for urine versus plasma markers.

Associations between ln(uAs) or ln(toenail As) and ln-transformed biomarkers were evaluated using linear regression models. Covariates considered for inclusion in regression models based on a priori considerations and data availability were sex, education, age, cigarette smoking status, alcohol consumption history, ln(BMI), batch assignment, water intake, and fish consumption. Potential confounders that did not alter coefficients by ≥10% (considering all other potential confounders) were removed from the final models. Our final models were adjusted for sex, age, alcohol consumption, smoking status, and batch assignment, with additional adjustment for arsenobetaine when uAs was the exposure of interest. In models exploring 15-F2t-IsoP, additional adjustment was included for SG. We further assessed the relationships between %uiAs, %uMMA, or %uDMA and all biomarkers. These models were adjusted for the same set of covariates but also included adjustment for total uAs. In sensitivity analyses, we investigated the potential impact of including water intake as a covariate in our models, as well as excluding individuals with high water As (>50 μg/L). We also examined the impact of excluding individuals with out-of-reference range SG values. Exploratory analyses of interactions between As measures and sex were evaluated using cross-product terms in linear regression models. For all analyses, we performed complete case analyses, where observations with missingness in a covariate were excluded. A p-value of 0.05 (2-sided) was used as a cut-off to evaluate statistical significance.


General Characteristics

General demographic characteristics of the study participants are shown in Table 1. More than half of the study participants were ≥65 y old, with a mean age of 64 y. Approximately 39% of participants were women (as a result of frequency-matching in the parent case–control study), 62% were at least college educated, and 80% were currently married. Arsenic levels in water, shown in Table 2, ranged from 0.001 to 110.5 μg/L, and approximately 5% of our study sample had water As levels exceeding the maximum contaminant level of 10 μg/L. Total urinary As levels (excluding arsenobetaine) among participants ranged from 0.825 to 103.42 μg/L, and the percentage of uAs metabolites ranged from 0.7% to 36.5%, 1.0% to 26.4% and 42.3% to 97.7% for %uiAs, %uMMA and %uDMA, respectively. Three individuals had levels of the plasma biomarkers VCAM-1 and ICAM-1 below the detection limit (Table 2). (see Table S1 for study participant characteristics shown separately by sex). The average BMI was higher in men than in women, and alcohol consumption was also generally higher among men. Men were also more likely to be currently married. Although total As exposures did not differ significantly by sex, women on average had a lower %uiAs and %uMMA, and a higher %uDMA, than men. On average, women also had higher plasma ICAM-1 (357.6±164.7 ng/mL) than men (322.6±142.6 ng/mL) and somewhat higher, albeit not significant, levels of MMP-9 (1,255.7±1,168.8 pg/mL versus 980.8±683.8 pg/mL among men). Although raw urine 15-F2t-IsoP concentrations were significantly higher in men (4.8±3.6 ng/mL) than in women (4.0±3.5 ng/mL), SG-adjusted 15-F2t-IsoP measures did not significantly differ by sex (men, 4.5±3.3 ng/mL versus women, 4.7±3.6 ng/mL).


Table 1. Demographic characteristics of study participants (n=418).
Characteristic Mean±SD or n (%) Minimum 25th percentile Median 75th percentile Maximum
Age (y) 64±8 26 60 66 70 75
Age ≥65 y 235 (56.2)
Men 254 (60.8)
Women 164 (39.2)
BMI (kg/m2) 28.5±5.5 16.1 24.4 27.4 31.8 49.1
High school education or less 160 (38.3)
College educated or higher 258 (61.7)
Currently married 334 (79.9)
Alcohol consumption status
  Never drinker 64 (15.3)
  Former drinker 52 (12.7)
  Current drinker <median (<336 g/mo) 151 (36.1)
  Current drinker ≥median (≥336 g/mo) 150 (35.9)
Smoking status
  Never smoker 157 (37.6)
  Former smoker 203 (48.6)
  Current smoker 58 (13.9)
Fish consumption
  Consumed fish ≥1 time per month 361 (88.9)
  Consumed fish <1 time per month 45 (11.1)
  Missing fish consumption 12
  Urine specific gravity 1.02±0.01 1.00 1.01 1.02 1.02 1.04
Note: Data are complete for all variables unless otherwise indicated. All measured variables were above the limit of detection (LOD) unless otherwise indicated. BMI, body mass index.


Table 2. Descriptive information on As exposure and outcome biomarkers among study participants (n=418).
Arsenic exposure Mean±SD or n (%) Minimum 25th percentile Median 75th percentile Maximum
Water As (μg/L) 2.6±9.4 0.0 0.1 0.3 0.9 110.5
Water As below LOD 17 (4.1)
Water arsenic <10 μg/L MCL 394 (94.7)
Water arsenic ≥10 μg/L MCL 22 (5.3)
Water arsenic ≥50 μg/L 4 (1.0)
Missing water As 2 (0.5)
Toenail As (μg/g) 5.3±31.2 0.0 0.0 0.1 2.0 507.2
Total uAs, excluding arsenobetaine (μg/L)a 7.1±8.4 0.8 3.1 4.9 8.2 103
Missing total uAs 15 (3.3)
Urinary arsenobetaine (μg/L) 30.2±87.6 0.0 1.3 5.7 26.2 1276.1
Urinary arsenobetaine below LOD 5 (1.2)
Missing urinary arsenobetaine 15 (3.3)
%uiAsb 8.3±5.7 0.7 4.6 7.3 10.3 38.6
%uMMAb 10.6±4.6 1.0 7.4 10.2 13.1 29.2
%uDMAb 81.1±8.7 38.3 76.7 82.0 87.1 97.7
Missing %As metabolites 15 (3.3)
Outcome biomarkers
  Plasma VCAM-1 (ng/mL) 224.4±96.9 1.4 166.3 201.9 260.4 1084.9
  Plasma VCAM-1 below LOD 3 (0.8)
  Missing plasma VCAM-1 22 (5.2)
  Plasma ICAM-1 (ng/mL) 336.5±152.5 0.9 234.8 311.3 402.3 1245.0
  Plasma ICAM-1 below LOD 3 (0.8)
  Missing ICAM-1 22 (5.2)
  Plasma MMP-9 (pg/mL) 1090±916 148 530 800 1407 7216
  Missing plasma MMP-9 22 (5.2)
  Plasma TNF-α (pg/mL) 148±167 22 98 130 166 2995
  Missing plasma TNF-α 22 (5.2)
  Plasma PAI-1 (ng/mL) 38.7±17.5 14.8 26.6 36.3 46.5 141.1
  Missing plasma PAI-1 51 (12.2)
  Urine 15-F2t-IsoP (ng/mL) 4.5±3.6 0.3 2.5 3.5 5.5 33.8
Note: Data are complete for all variables unless otherwise indicated. All measured variables were above the LOD unless otherwise indicated. 15-F2t-IsoP, 15-F2t-isoprostane; As, arsenic; BMI, body mass index; ICAM-1, intercellular adhesion molecule 1; LOD, limit of detection; MMP-9, matrix metalloproteinase 9; PAI-1, plasminogen activator inhibitor-1; TNF-α, tumor necrosis factor-α; uAs, urine arsenic; %uDMA, proportion of dimethyl arsenical species in urine; %uiAs, proportion of inorganic arsenical species in urine; %uMMA, proportion of monomethyl arsenical species in urine; VCAM-1, vascular cell adhesion molecule 1.

aNo values for total uAs were below the LOD because total uAs is calculated as a sum of As metabolite measures, and any As metabolites below the LOD were imputed to LOD/√2 before variable calculation.

bAny As metabolites below the LOD were imputed to LOD/√2 before calculation of metabolite percentages.

Associations between As Measures, %As Metabolites, and Biomarkers of Potential CVD Risk

Associations between As measures and each biomarker are shown in Table 3, presented as the percent difference in each marker per doubling of toenail or urinary As. Toenail As was positively associated with VCAM-1, such that a doubling of toenail As was associated with a 1.7% increase in plasma VCAM-1 concentration {[95% confidence interval (CI): 0.20, 3.22]; p=0.03}. Positive associations were observed between toenail As and both ICAM-1 [1.46% increase (95% CI: −0.16, 3.11); p=0.08] and 15-F2t-IsoP [1.65% increase (95% CI: 0.03, 3.29); p=0.05). Additionally, a doubling in uAs was associated with an 8.8% [(95% CI: 3.15, 14.69); p<0.01] higher 15-F2t-IsoP concentration in urine; uAs was not related to any of the other biomarkers. In contrast with the other findings, a doubling of toenail As was associated with a 2.29% [(95% CI: −4.25, −0.29); p=0.03] decrease in plasma MMP-9. Exploratory analyses of associations between total urine or toenail As measures and biomarkers did not appear to differ significantly by sex (p≥0.10 for all cross-product interaction terms) (see Tables S2 and S3).


Table 3. Percent difference (95% CI) in outcome biomarkers for a doubling of arsenic exposure biomarkers.
Biomarker Toenail As Urinary As
n Percent difference (95% CI) p-Value n Percent difference (95% CI) p-Value
VCAM-1 396 1.70 (0.20, 3.22) 0.03 347 −4.61 (−10.52, 1.68) 0.15
ICAM-1 396 1.46 (−0.16, 3.11) 0.08 347 −4.25 (−10.60, 2.56) 0.21
MMP-9 396 −2.29 (−4.25, −0.29) 0.03 347 3.25 (−5.07, 12.29) 0.45
TNF-α 396 0.23 (−1.02, 1,50) 0.72 347 −3.16 (−8.11, 2.07) 0.23
PAI-1 367 0.85 (−0.43, 2.14) 0.19 322 −1.19 (−6.31, 4.22) 0.66
15-F2t-IsoPa 418 1.65 (0.03, 3.29) 0.05 403 8.77 (3.15, 14.69) <0.01
Note: Percent difference was calculated using the following formula: {[(2β)−1]×100}, where β is the arsenic coefficient from linear regression models in which both the arsenic exposure variable and the biomarker were natural log–transformed. Models were adjusted for sex, age, alcohol consumption, cigarette smoking status, and analytic batch. Urine arsenic analyses were additionally adjusted for ln(specific gravity–adjusted arsenobetaine). 15-F2t-IsoP, 15-F2t-isoprostane; As, arsenic; CI, confidence interval; ICAM-1, intercellular adhesion molecule 1; MMP-9, matrix metalloproteinase 9; PAI-1, plasminogen activator inhibitor-1; uAs, urine arsenic; TNF-α, tumor necrosis factor-α; VCAM-1, vascular cell adhesion molecule 1.

aFor 15-F2t-IsoP models, uAs was not adjusted for specific gravity. Instead, specific gravity was included as a covariate in models.

We further assessed associations between %As metabolites and each biomarker, which are shown in Table 4 as the percent difference in each marker for a 5% increase in As metabolite. A 5% increase in %uMMA was associated with a 7.92% increase [(95% CI: 2.10, 14.07); p=0.01] in 15-F2t-IsoP, whereas a 5% increase in %uDMA was associated with a 2.98% decrease [(95% CI: −6.07, 0.21); p=0.06] in 15-F2t-IsoP. %As metabolites were not related to any of the other biomarkers, with the exception of PAI-1, which in contrast to other findings was negatively associated with %uMMA [−7.67% (95% CI: −12.56, −2.51); p<0.01). We performed exploratory analyses of associations with arsenic metabolite percentages by sex, but the estimates were imprecise, and there were no significant differences in associations between men and women for any of the metabolites or outcomes (see Table S4).


Table 4. Percent difference (95% CI) in outcome biomarkers for a 5% increase in arsenic metabolites.
Biomarker %uiAs %uMMA %uDMA
n Percent difference (95% CI) p-Value Percent difference (95% CI) p-Value Percent difference (95% CI) p-Value
VCAM-1 347 2.30 (−2.88, 7.75) 0.39 3.76 (−2.79, 10.75) 0.27 −2.13 (−5.54, 1.40) 0.23
ICAM-1 347 3.30 (−2.30, 9.23) 0.25 1.99 (−4.92, 9.41) 0.58 −2.08 (−5.74, 1.73) 0.28
MMP-9 347 −1.70 (−8.19, 5.26) 0.62 −5.86 (−13.58, 2.56) 0.17 2.62 (−2.06, 7.52) 0.28
TNF-α 347 −0.15 (−4.33, 4.22) 0.95 −2.20 (−7.31, 3.20) 0.42 0.73 (−2.17, 3.72) 0.62
PAI-1 322 1.44 (−2.88, 5.95) 0.52 −7.67 (−12.56, −2.51) <0.01 1.68 (−1.30, 4.74) 0.27
15-F2t-IsoP 403 0.97 (−3.66, 5.83) 0.69 7.92 (2.10, 14.07) <0.01 −2.98 (−6.07, 0.21) 0.07
Note: The percent difference was calculated using the following formula: {[(e5×β)−1]×100}, where β is the arsenic coefficient from linear regression models in which only the outcome biomarker variable was natural log–transformed. Models were adjusted for sex, age, smoking status, alcohol status, analytic batch, ln[specific gravity (SG)–adjusted arsenobetaine], and ln(SG-adjusted uAs). In 15-F2t-IsoP models evaluating urinary arsenic, SG was included as a covariate in models and urinary measures (uAs, urinary arsenobetaine, and 15-F2t-IsoP) were not adjusted for SG. 15-F2t-IsoP, 15-F2t-isoprostane; CI, confidence interval; uAs, total urine arsenic; %uDMA, proportion of dimethyl arsenical species in urine; %uiAs, proportion of inorganic arsenical species in urine; %uMMA, proportion of monomethyl arsenical species in urine.

Finally, we performed a number of additional sensitivity analyses. First, we estimated associations between arsenic exposure and 15-F2t-IsoP, VCAM-1, and ICAM-1 after excluding five participants with water As >50 μg/L (see Table S5). Associations were similar to those in the primary models. We also repeated the analyses after excluding six participants with urine SG values outside of the normal reference range, but none of the point estimates differed from the primary analysis by >5% (data not shown). We also tested the potential impact of including water intake as a covariate in our analyses of urine As and 15-F2t-IsoP and found that our estimates were not substantially altered by this additional adjustment (see Table S6).


Arsenic is thought to contribute to the development of cardiovascular disease by increasing the production of reactive oxygen species, which may mediate inflammatory responses, alterations in gene expression, and impaired nitric oxide signaling (Solenkova et al. 2014; States et al. 2009; Wu et al. 2014). These factors might also contribute to endothelial dysfunction and altered vascular tone, ultimately increasing the risk for hypertension and atherosclerosis (Solenkova et al. 2014; States et al. 2009; Wu et al. 2014). In this cross-sectional study of U.S. men and women, we evaluated associations between As exposure and a urinary indicator of oxidative stress (15-F2t-IsoP) and circulating markers of endothelial dysfunction (VCAM-1, ICAM-1, PAI-1) and inflammation (MMP-9, TNF-α). Toenail As, an indicator of As exposure in the previous 6–12 mo (NRC 2013), was associated with significantly higher plasma VCAM-1 and urine 15-F2t-IsoP concentrations and with a nonsignificant increase in plasma ICAM-1 (p=0.08). However, toenail As was also associated with significantly lower plasma MMP. Urine As, which represents more recent As exposure, largely from the previous two days (NRC 2013), was associated with higher urinary 15-F2t-IsoP concentrations. %MMA in urine was associated with higher 15-F2t-IsoP, suggesting that As methylation capacity is reduced in association with oxidative stress. However, %MMA was also associated with significantly lower plasma PAI-1.

CVD is a complex outcome with multiple etiologic pathways. Arsenic is hypothesized to affect several of these pathways, including oxidative signaling, induction of cytokines, systemic inflammation, and vascular endothelial activation. During inflammation or endothelial injury, leukocytes are recruited to the microenvironment by a combination of chemokines and adhesion molecules. VCAM-1 and ICAM-1 are often expressed at lesion-prone sites, with VCAM-1 expression preceding atherosclerotic plaque development (Mozos et al. 2017; Nakashima et al. 1998; Poredoš and Ježovnik 2015). Monocytes, attracted to the lesion by these adhesion molecules, penetrate the arterial intima, where they take on a tissue macrophage-like phenotype, secreting cytokines and matrix metalloproteinases, such as MMP-9, which degrade the extracellular matrix and thereby promote disease progression (Libby et al. 2002). Elevated levels of VCAM-1 and ICAM-1 have been previously related to a number of risk factors for CVD and metabolic disease, such as obesity, hypertension, diabetes, and carotid intima media thickness (Blankenberg et al. 2003; Bosanská et al. 2010; Hwang et al. 1997; Pankow et al. 2016). Although previous studies have reported a positive association between these markers and an increased risk of CVD morbidity and mortality (Hwang et al. 1997; Ridker et al. 1998; Rohde et al. 1998), a more recent study reported an inverse association between prospectively measured VCAM-1 levels and CVD risk, suggesting that this association may require further investigation (Kunutsor et al. 2017). Furthermore, it is unclear whether relatively small changes in these plasma markers, such as those observed in the present study, may be clinically relevant or related to elevated CVD risk. In this study, toenail As was associated with significantly higher serum VCAM-1 and with a nonsignificant increase in serum ICAM-1 (p=0.08), which indicate early cardiovascular effects and are consistent with findings for other As-exposed populations. VCAM-1 and ICAM-1 have been previously related to chronic As exposure across multiple populations, including evidence from studies in Bangladesh (Chen et al. 2007; Karim et al. 2013; Wu et al. 2012) as well as from recent findings by our group in a New Hampshire pregnancy cohort that maternal urine As is associated with higher levels of both maternal plasma VCAM-1 and infant cord blood VCAM-1 and ICAM-1 levels (Farzan et al. 2017). However, our findings also suggest a possible inverse relationship between As and MMP-9, which is inconsistent with the proposed mechanism. More work is needed to elucidate whether altered levels of these markers are related to development of disease.

Although previous studies have linked As exposure with altered levels of plasma markers of inflammation and endothelial function, including VCAM-1 and ICAM-1 (Burgess et al. 2013; Chen et al. 2007; Kurzius-Spencer et al. 2016; Wu et al. 2012), few have examined associations at environmentally relevant levels of As exposure (generally <100 μg/L), such as those found in most of New Hampshire and across the United States in private wells. Our results suggest that, similar to what has been reported for populations exposed to relatively high levels of As, such as populations in Bangladesh, relatively low levels of As exposure may influence inflammation and other mechanisms involved in CVD pathogenesis. The idea that lower levels of As exposure could play a role in CVD development has been supported by an increasing number of epidemiological studies from our research group (Farzan et al. 2015a, 2015b) and from others (D’Ippoliti et al. 2015; Gong and O’bryant 2012; James et al. 2015; Medrano et al. 2010; Monrad et al. 2017; Moon et al. 2013; Mordukhovich et al. 2009). Experimental studies have also shown that As can elicit adverse cardiovascular effects at doses much lower than those required to induce cancer (Lemaire et al. 2011, 2015; Soucy et al. 2005; Straub et al. 2007). For example, a recent mouse study demonstrated that As concentrations as low as 10 ppb increase monocyte adhesion to the endothelium via enhanced VCAM-1 binding (Lemaire et al. 2015). Given the potential for widespread low to moderate As exposure from both water and food sources (Davis et al. 2017; Navas-Acien and Nachman 2013), even relatively small As-related contributions to disease risk could have broad implications for public health.

Reactive oxygen species produced by As exposure are known to induce a wide range of effects that are thought to underlie a number of chronic health conditions, including CVD (reviewed in Jomova et al. 2011; Wu et al. 2014). Oxidative stress responses are thought to be linked to endothelial dysfunction, as indicated by their ability to induce VCAM-1 and ICAM-1 expression (Wadham et al. 2004). Experimental and epidemiological studies have reported associations between As exposure and higher levels of oxidative stress biomarkers, such as oxidized low density lipoprotein and oxidative DNA damage biomarker 8-oxo-2′-deoxyguanosine (Engström et al. 2010; Karim et al. 2013). Although As exposure has been shown to induce 8-isoprostane levels in vitro (Han et al. 2005), to our knowledge, the relationship between As exposure and isoprostanes has not been evaluated in human populations. Isoprostanes are prostaglandin-like compounds that are endogenously generated by nonenzymatic free-radical-catalyzed peroxidation of esterified arachidonic acid. Elevated urinary F2-IsoP is thought to reflect widespread oxidative stress and systemic levels of lipid peroxidation end products, and it has been positively associated with CVD risk factors, such as smoking and hypertension (Minuz et al. 2002; Morrow et al. 1995); our results suggest that this marker may also increase with As exposure. In our study, we measured the major urinary metabolite 15-F2t-IsoP, which is thought to be a reliable marker of systemic oxidative stress (Dorjgochoo et al. 2012; Milne et al. 2015). Additionally, 15-F2t-IsoP is not subject to collection-related oxidation artifact, is not influenced by dietary lipid content, and is stable over time if samples are stored at −80°C (Morrow et al. 1999; Prasain et al. 2013). However, the extent to which levels of 15-F2t-IsoP measured in urine may be influenced by local conditions in the bladder remains unclear. Experimental animal studies have demonstrated that the bladder can produce 15-F2t-IsoP, but the extent to which levels measured in our subjects may be influenced by conditions in the bladder is not known. We cannot rule out that production of 15-F2t-IsoP by the bladder epithelium could have influenced our measurements (Tarcan et al. 2000). Further research is needed to establish whether F2-IsoP is a reliable marker of As-related oxidative stress and whether alterations in its levels may be related to development of CVD.

Notably, we observed differential associations between the urinary As metabolites and 15-F2t-IsoP. Previous studies have reported that individuals with higher %uMMA or a lower ratio of uDMA to uMMA have a higher risk of many As-related health outcomes (Steinmaus et al. 2010), including carotid intima-media thickness and CVD (Chen et al. 2013a, 2013b). Our findings that urine and toenail As levels were associated with higher urine concentrations of the oxidative stress marker 15-F2t-IsoP and that individuals with higher %uMMA had higher urine 15-F2t-IsoP, whereas those with higher %uDMA had lower 15-F2t-IsoP, suggest that an enhanced ability to metabolize iAs to DMA might reduce oxidative stress resulting from As exposure. Previous studies in more highly exposed populations have reported that women appear to be more efficient at metabolizing iAs to DMA than men, and it has been suggested that this may contribute to sex differences in certain As-related health outcomes, such as skin lesions (Ahsan et al. 2006; Jansen et al. 2015; Lindberg et al. 2008). Consistent with previous studies, we observed that on average, women had lower %uiAs and %uMMA and higher %uDMA than men. However, our findings with regard to sex differences in associations between the measured biomarkers and the distribution of urine As metabolites were inconclusive.

Unexpectedly, we found that toenail As was inversely associated with plasma MMP-9, which is known to play a role in several stages of atherosclerosis and has been prospectively linked to CVD mortality (Hansson et al. 2009, 2011). However, the relationship between As exposure and plasma MMP-9 has been somewhat inconsistent across studies. For example, two cross-sectional studies in the United States and Mexico reported positive associations between As exposure and serum MMP-9 (Burgess et al. 2013; Kurzius-Spencer et al. 2016). However, this finding was not confirmed by a prospective study in Bangladesh: In that study, no overall associations between As exposure and MMP-9 were observed, but slight decreases were found in MMP-9 levels at moderate urinary As concentrations, suggesting a possible nonmonotonic relationship (Wu et al. 2012). Although there are a number of potential reasons for these inconsistencies, it is possible that differences in exposure metrics (e.g., water/food As, urine As, and toenail As) or variability in methods of MMP-9 detection could have affected our ability to compare across studies. Given the importance of MMP-9 as a marker of CVD, these conflicting findings warrant further investigation.

Importantly, our study had several weaknesses. First, because our study was a cross-sectional analysis, some of our findings may be subject to reverse causality. For example, there is some evidence that As may adversely affect renal function (Zheng et al. 2015; reviewed in Zheng et al. 2014) and, though not extensively studied, it has been hypothesized that reduced renal function may affect the distribution of As metabolites in urine (Peters et al. 2015; Zheng et al. 2015). Thus, individuals with subclinical or clinical CVD may have increased biomarkers of oxidative stress, endothelial dysfunction, or inflammation in addition to reduced renal function and may therefore have an altered distribution of As metabolites in urine. We also lacked information on participants’ CVD status and other potential health conditions at the time of the interview and were unable to account for this in our models. Further, our sample size was insufficient to evaluate the shape of the dose–response relationships for each exposure and outcome in detail. Future studies evaluating arsenic exposure in relation to these markers in larger study populations would be helpful in exploring potential nonmonotonic relationships. Urinary arsenic was only measured at a single time point; therefore, the potential variability in typical exposure levels may not be taken into account for all of the individuals in our study sample. Urinary arsenic is considered to be a reliable measure of recent arsenic exposure that appears to remain relatively consistent over time in adults (Gamble et al. 2006), but differences in short- versus long-term windows of exposure reflected by urine and toenails may be responsible for some of the inconsistencies in our findings. Finally, because our study population consisted almost entirely of Caucasian older adults residing in New Hampshire, our findings may not be generalizable to other populations in the United States or elsewhere.

Our study also had many strengths. One strength of our study was the measurement of both toenail As and uAs, which allowed us to estimate associations for both long-term and recent As exposure on a suite of biomarkers of potential CVD risk. The use of urine as an As biomarker provided a measure of As exposure from various sources including diet and drinking water. Additionally, we acquired speciated uAs measures and were therefore able to also evaluate associations between the different As metabolites, which may have differing toxicities, in relation to the same biomarkers. Although one previous study has evaluated %uMMA in relation to plasma MMP-9 and did not observe a significant association (Burgess et al. 2013), to our knowledge, associations between As metabolites and other biomarkers potentially relevant to CVD have not yet been studied.


In our cross-sectional study population of U.S. adults, most of whom had low to moderate As exposure, As was positively associated with biomarkers that may be relevant to CVD pathogenesis, including VCAM-1, ICAM-1, and 15-F2t-IsoP, although an inverse association with MMP-9 was also observed. Furthermore, lower %uMMA and higher %uDMA, which may indicate more efficient As metabolism, was inversely associated with urine 15-F2t-IsoP, a marker of oxidative stress.


We thank R. Andreozzi for carrying out the plasma biomarker assays.

This research was funded by National Institutes of Health (NIH) grants R00 ES024144, T32 ES013678, R01 CA057494, and National Institute of General Medical Sciences (NIGMS) grant P20GM104416. Multiplex cytokine assays were carried out in DartLab, the Immune Monitoring and Flow Cytometry Shared Resource, supported by a National Cancer Institute Cancer Center Support Grant to the Norris Cotton Cancer Center (P30CA023108-37) and by an Immunology Centers of Biomedical Research Excellence (COBRE) grant (P30GM103415-15) from NIGMS.


Ahsan H, Chen Y, Parvez F, Zablotska L, Argos M, Hussain I, et al. 2006. Arsenic exposure from drinking water and risk of premalignant skin lesions in Bangladesh: Baseline results from the Health Effects of Arsenic Longitudinal Study. Am J Epidemiol 163(12):1138–1148, PMID: 16624965, 10.1093/aje/kwj154.

Blankenberg S, Barbaux S, Tiret L. 2003. Adhesion molecules and atherosclerosis. Atherosclerosis 170(2):191–203, PMID: 14612198, 10.1016/S0021-9150(03)00097-2.

Bosanská L, Michalský D, Lacinová Z, Dostálová I, Bártlová M, Haluzíková D, et al. 2010. The influence of obesity and different fat depots on adipose tissue gene expression and protein levels of cell adhesion molecules. Physiol Res 59(1):79, PMID: 19249917.

Burgess JL, Kurzius-Spencer M, O’rourke MK, Littau SR, Roberge J, Meza-Montenegro MM, et al. 2013. Environmental arsenic exposure and serum matrix metalloproteinase-9. J Expo Sci Environ Epidemiol 23(2):163–169, PMID: 23232971, 10.1038/jes.2012.107.

Chen Y, Santella RM, Kibriya MG, Wang Q, Kappil M, Verret WJ, et al. 2007. Association between arsenic exposure from drinking water and plasma levels of soluble cell adhesion molecules. Environ Health Perspect 115(10):1415–1420, PMID: 17938729, 10.1289/ehp.10277.

Chen Y, Wu F, Graziano JH, Parvez F, Liu M, Paul RR, et al. 2013a. Arsenic exposure from drinking water, arsenic methylation capacity, and carotid intima-media thickness in Bangladesh. Am J Epidemiol 178(3):372–381, PMID: 23788675, 10.1093/aje/kwt001.

Chen Y, Wu F, Liu M, Parvez F, Slavkovich V, Eunus M, et al. 2013b. A prospective study of arsenic exposure, arsenic methylation capacity, and risk of cardiovascular disease in Bangladesh. Environ Health Perspect 121(7):832–838, PMID: 23665672, 10.1289/ehp.1205797.

Dabitao D, Margolick JB, Lopez J, Bream JH. 2011. Multiplex measurement of proinflammatory cytokines in human serum: comparison of the Meso Scale Discovery electrochemiluminescence assay and the cytometric bead array. J Immunol Methods 372(1–2):71–77, PMID: 21781970, 10.1016/j.jim.2011.06.033.

Davis MA, Li Z, Gilbert-Diamond D, Mackenzie TA, Cottingham KL, Jackson BP, et al. 2014. Infant toenails as a biomarker of in utero arsenic exposure. J Expo Sci Environ Epidemiol 24(5):467–473, PMID: 24896769, 10.1038/jes.2014.38.

Davis MA, Signes-Pastor AJ, Argos M, Slaughter F, Pendergrast C, Punshon T, et al. 2017. Assessment of human dietary exposure to arsenic through rice. Sci Total Environ 586:1237–1244, PMID: 28233618, 10.1016/j.scitotenv.2017.02.119.

D’Ippoliti D, Santelli E, De Sario M, Scortichini M, Davoli M, Michelozzi P. 2015. Arsenic in drinking water and mortality for cancer and chronic diseases in central Italy, 1990–2010. PLoS One 10(9):e0138182, PMID: 26383851, 10.1371/journal.pone.0138182.

Dorjgochoo T, Gao YT, Chow WH, Shu XO, Yang G, Cai QY, et al. 2012. Major metabolite of F2-isoprostane in urine may be a more sensitive biomarker of oxidative stress than isoprostane itself. Am J Clin Nutr 96(2):405–414, PMID: 22760572, 10.3945/ajcn.112.034918.

Duty SM, Ackerman RM, Calafat AM, Hauser R. 2005. Personal care product use predicts urinary concentrations of some phthalate monoesters. Environ Health Perspect 113(11):1530–1535, PMID: 16263507, 10.1289/ehp.8083.

Engström KS, Vahter M, Johansson G, Lindh CH, Teichert F, Singh R, et al. 2010. Chronic exposure to cadmium and arsenic strongly influences concentrations of 8-oxo-7, 8-dihydro-2′-deoxyguanosine in urine. Free Radic Biol Med 48(9):1211–1217, PMID: 20153423, 10.1016/j.freeradbiomed.2010.02.004.

Farzan SF, Brickley EB, Li Z, Gilbert-Diamond D, Gossai A, Chen Y, et al. 2017. Maternal and infant inflammatory markers in relation to prenatal arsenic exposure in a U.S. pregnancy cohort. Environ Res 156:426–433, PMID: 28410520, 10.1016/j.envres.2017.03.056.

Farzan SF, Chen Y, Rees JR, Zens MS, Karagas MR. 2015a. Risk of death from cardiovascular disease associated with low-level arsenic exposure among long-term smokers in a US population-based study. Toxicol Appl Pharmacol 287(2):93–97, PMID: 26048586, 10.1016/j.taap.2015.05.013.

Farzan SF, Chen Y, Wu F, Jiang J, Liu M, Baker E, et al. 2015b. Blood pressure changes in relation to arsenic exposure in a U.S. pregnancy cohort. Environ Health Perspect 123(10):999–1006, PMID: 25793356, 10.1289/ehp.1408472.

Flanagan SM, Belaval M, Ayotte JD. 2014. Arsenic, iron, lead, manganese, and uranium concentrations in private bedrock wells in southeastern New Hampshire, 2012–2013. U.S. Geological Survey Fact Sheet, 2014–3042. [accessed 30 November 2017]

Gamble MV, Liu X, Ahsan H, Pilsner JR, Ilievski V, Slavkovich V, et al. 2006. Folate and arsenic metabolism: a double-blind, placebo-controlled folic acid-supplementation trial in Bangladesh. Am J Clin Nutr 84(5):1093–1101, PMID: 17093162, 10.1097/00001648-200611001-01422.

Gilbert-Diamond D, Cottingham KL, Gruber JF, Punshon T, Sayarath V, Gandolfi AJ, et al. 2011. Rice consumption contributes to arsenic exposure in US women. Proc Natl Acad Sci USA
108(51):20656–20660, PMID: 22143778, 10.1073/pnas.1109127108.

Gilbert-Diamond D, Li Z, Perry AE, Spencer SK, Gandolfi AJ, Karagas MR. 2013. A population-based case–control study of urinary arsenic species and squamous cell carcinoma in New Hampshire, USA. Environ Health Perspect 121(10):1154–1160, PMID: 23872349, 10.1289/ehp.1206178.

Gong G, O’Bryant SE. 2012. Low-level arsenic exposure, AS3MT gene polymorphism and cardiovascular diseases in rural Texas counties. Environ Res 113:52–57, PMID: 22341486, 10.1016/j.envres.2012.01.003.

Han SG, Castranova V, Vallyathan V. 2005. Heat shock protein 70 as an indicator of early lung injury caused by exposure to arsenic. Mol Cell Biochem 277(1–2):153–164, PMID: 16132727, 10.1007/s11010-005-5874-y.

Hansson J, Lind L, Hulthe J, Sundström J. 2009. Relations of serum MMP-9 and TIMP-1 levels to left ventricular measures and cardiovascular risk factors: a population-based study. Eur J Cardiovasc Prev Rehabil 16(3):297–303, PMID: 19387352, 10.1097/HJR.0b013e3283213108.

Hansson J, Vasan RS, Ärnlöv J, Ingelsson E, Lind L, Larsson A, et al. 2011. Biomarkers of extracellular matrix metabolism (MMP-9 and TIMP-1) and risk of stroke, myocardial infarction, and cause-specific mortality: Cohort study. PloS One 6(1):e16185, PMID: 21283828, 10.1371/journal.pone.0016185.

Hwang S-J, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM, et al. 1997. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation 96(12):4219–4225, PMID: 9416885, 10.1161/01.CIR.96.12.4219.

James KA, Byers T, Hokanson JE, Meliker JR, Zerbe GO, Marshall JA. 2015. Association between lifetime exposure to inorganic arsenic in drinking water and coronary heart disease in Colorado residents. Environ Health Perspect 123(2):128–134, PMID: 25350952, 10.1289/ehp.1307839.

Jansen RJ, Argos M, Tong L, Li J, Rakibuz-Zaman M, Islam MT, et al. 2015. Determinants and consequences of arsenic metabolism efficiency among 4,794 individuals: Demographics, lifestyle, genetics, and toxicity. Cancer Epidemiol Biomarkers Prev 25(2):381–90, PMID: 26677206, 10.1158/1055-9965.EPI-15-0718.

Jomova K, Jenisova Z, Feszterova M, Baros S, Liska J, Hudecova D, et al. 2011. Arsenic: Toxicity, oxidative stress and human disease. J Appl Toxicol 31(2):95–107, PMID: 21321970, 10.1002/jat.1649.

Karagas MR, Greenberg ER, Spencer SK, Stukel TA, Mott LA. 1999. Increase in incidence rates of basal cell and squamous cell skin cancer in New Hampshire, USA. New Hampshire Skin Cancer Study Group. Int J Cancer 81(4):555–559, PMID: 10225444, 10.1002/(SICI)1097-0215(19990517)81:4<555::AID-IJC9>3.0.CO;2-R.

Karagas MR, Nelson HH, Sehr P, Waterboer T, Stukel TA, Andrew A, et al. 2006. Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin. J Natl Cancer Inst 98(6):389–395, PMID: 16537831, 10.1093/jnci/djj092.

Karagas MR, Stukel TA, Morris JS, Tosteson TD, Weiss JE, Spencer SK, et al. 2001. Skin cancer risk in relation to toenail arsenic concentrations in a US population-based case–control study. Am J Epidemiol 153(6):559–565, PMID: 11257063, 10.1093/aje/153.6.559.

Karagas MR, Tosteson TD, Blum J, Morris JS, Baron JA, Klaue B. 1998. Design of an epidemiologic study of drinking water arsenic exposure and skin and bladder cancer risk in a U.S. population. Environ Health Perspect 106 (suppl 4):1047–1050, PMID: 9703491, 10.2307/3434150.

Karim MR, Rahman M, Islam K, Al Mamun A, Hossain S, Hossain E, et al. 2013. Increases in oxidized low-density lipoprotein and other inflammatory and adhesion molecules with a concomitant decrease in high-density lipoprotein in the individuals exposed to arsenic in Bangladesh. Toxicol Sci 135(1):17–25, PMID: 23761297, 10.1093/toxsci/kft130.

Kunutsor SK, Bakker SJ, Dullaart RP. 2017. Soluble vascular cell adhesion molecules may be protective of future cardiovascular disease risk: findings from the PREVEND prospective cohort study. J Atheroscler Thromb 24(8) 804–818, PMID: 28202840, 10.5551/jat.38836.

Kurzius-Spencer M, Harris RB, Hartz V, Roberge J, Hsu C-H, O’Rourke MK, et al. 2016. Relation of dietary inorganic arsenic to serum matrix metalloproteinase-9 (MMP-9) at different threshold concentrations of tap water arsenic. J Expo Sci Environ Epidemiol 6(5):445–451, PMID: 25605447, 10.1038/jes.2014.92.

Lemaire M, Lemarié CA, Molina MF, Schiffrin EL, Lehoux S, Mann KK. 2011. Exposure to moderate arsenic concentrations increases atherosclerosis in APOE-/- mouse model. Toxicol Sci 122(1):211–221, PMID: 21512104, 10.1093/toxsci/kfr097.

Lemaire M, Negro Silva LF, Lemarié CA, Bolt AM, Flores Molina M, Krohn RM, et al. 2015. Arsenic exposure increases monocyte adhesion to the vascular endothelium, a pro-atherogenic mechanism. PloS One 10(9):e0136592, PMID: 26332580, 10.1371/journal.pone.0136592.

Libby P, Ridker PM, Maseri A. 2002. Inflammation and atherosclerosis. Circulation 105(9):1135–1143, PMID: 11877368, 10.1161/hc0902.104353.

Lindberg A-L, Rahman M, Persson L-Å, Vahter M. 2008. The risk of arsenic induced skin lesions in Bangladeshi men and women is affected by arsenic metabolism and the age at first exposure. Toxicol Appl Pharmacol 230(1):9–16, PMID: 18336856, 10.1016/j.taap.2008.02.001.

Ma Y, Niu R, Sun Z, Wang J, Luo G, Zhang J, et al. 2012. Inflammatory responses induced by fluoride and arsenic at toxic concentration in rabbit aorta. Arch Toxicol 86(6):849–856, PMID: 22422340, 10.1007/s00204-012-0803-9.

Medrano MJ, Boix R, Pastor-Barriuso R, Palau M, Damián J, Ramis R, et al. 2010. Arsenic in public water supplies and cardiovascular mortality in Spain. Environ Res 110(5):448–454, PMID: 19880104, 10.1016/j.envres.2009.10.002.

Milne GL, Dai Q, Roberts LJ. 2015. The isoprostanes—25 years later. Biochim Biophys Acta 1851(4):433–445, PMID: 25449649, 10.1016/j.bbalip.2014.10.007.

Minuz P, Patrignani P, Gaino S, Degan M, Menapace L, Tommasoli R, et al. 2002. Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. Circulation 106(22):2800–2805, PMID: 12451006, 10.1161/01.CIR.0000039528.49161.E9.

Mo J, Xia Y, Wade TJ, DeMarini DM, Davidson M, Mumford J. 2011. Altered gene expression by low-dose arsenic exposure in humans and cultured cardiomyocytes: Assessment by real-time PCR arrays. Int J Environ Res Public Health 8(6):2090–2108, PMID: 21776218, 10.3390/ijerph8062090.

Monrad M, Ersbøll AK, Sørensen M, Baastrup R, Hansen B, Gammelmark A, et al. 2017. Low-level arsenic in drinking water and risk of incident myocardial infarction: A cohort study. Environ Res 154:318–324, PMID: 28157645, 10.1016/j.envres.2017.01.028.

Moon K, Guallar E, Navas-Acien A. 2012. Arsenic exposure and cardiovascular disease: An updated systematic review. Curr Atheroscler Rep 14(6):542–555, PMID: 22968315, 10.1007/s11883-012-0280-x.

Moon KA, Guallar E, Umans JG, Devereux RB, Best LG, Francesconi KA, et al. 2013. Association between exposure to low to moderate arsenic levels and incident cardiovascular disease: a prospective cohort study. Ann Intern Med 159(10):649–659, PMID: 24061511, 10.7326/0003-4819-159-10-201311190-00719.

Mordukhovich I, Wright RO, Amarasiriwardena C, Baja E, Baccarelli A, Suh H, et al. 2009. Association between low-level environmental arsenic exposure and QT interval duration in a general population study. Am J Epidemiol 170(6):739–746, PMID: 19700500, 10.1093/aje/kwp191.

Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, Shyr Y, et al. 1995. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers—smoking as a cause of oxidative damage. N Engl J Med 332(18):1198–1203, PMID: 7700313, 10.1056/NEJM199505043321804.

Morrow JD, Zackert WE, Yang JP, Kurhts EH, Callewaert D, Dworski R, et al. 1999. Quantification of the major urinary metabolite of 15-F2t-isoprostane (8-iso-PGF) by a stable isotope dilution mass spectrometric assay. Anal Biochem 269(2):326–331, PMID: 10222005, 10.1006/abio.1999.4008.

Mozos I, Malainer C, Horbańczuk J, Gug C, Stoian D, Luca CT, et al. 2017. Inflammatory markers for arterial stiffness in cardiovascular diseases. Front Immunol 8:1058, PMID: 28912780, 10.3389/fimmu.2017.01058.

Nakashima Y, Raines EW, Plump AS, Breslow JL, Ross R. 1998. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the APOE-deficient mouse. Arterioscler Thromb Vasc Biol 18(5):842–851, PMID: 9598845, 10.1161/01.ATV.18.5.842.

Navas-Acien A, Nachman KE. 2013. Public health responses to arsenic in rice and other foods. JAMA Intern Med 173(15):1395–1396, PMID: 23700006, 10.1001/jamainternmed.2013.6405.

NRC (National Research Council). 2013. Critical Aspects of EPA’s IRIS Assessment of Inorganic Arsenic: Interim Report. Washington, DC: National Academy of Sciences.

Pankow JS, Decker PA, Berardi C, Hanson NQ, Sale M, Tang W, et al. 2016. Circulating cellular adhesion molecules and risk of diabetes: The Multi-Ethnic Study of Atherosclerosis (MESA). Diabet Med 33(7):985–991, PMID: 26937608, 10.1111/dme.13108.

Peters BA, Hall MN, Liu X, Slavkovich V, Ilievski V, Alam S, et al. 2015. Renal function is associated with indicators of arsenic methylation capacity in Bangladeshi adults. Environ Res 143(Pt A):123–130, PMID: 26476787, 10.1016/j.envres.2015.10.001.

Poredoš P, Ježovnik MK. 2015. Markers of preclinical atherosclerosis and their clinical relevance. Vasa 44(4):247–256, PMID: 26314356, 10.1024/0301-1526/a000439.

Prasain JK, Arabshahi A, Taub PR, Sweeney S, Moore R, Sharer JD, et al. 2013. Simultaneous quantification of F2-isoprostanes and prostaglandins in human urine by liquid chromatography tandem-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 913–914:161–168, PMID: 23314354, 10.1016/j.jchromb.2012.12.009.

Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. 1998. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 351(9096):88–92, PMID: 9439492, 10.1016/S0140-6736(97)09032-6.

Rohde LE, Lee RT, Rivero J, Jamacochian M, Arroyo LH, Briggs W, et al. 1998. Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis. Arterioscler Thromb Vasc Biol 18(11):1765–1770, PMID: 9812916, 10.1161/01.ATV.18.11.1765.

Solenkova NV, Newman JD, Berger JS, Thurston G, Hochman JS, Lamas GA. 2014. Metal pollutants and cardiovascular disease: mechanisms and consequences of exposure. Am Heart J 168(6):812–822, PMID: 25458643, 10.1016/j.ahj.2014.07.007.

Soucy NV, Mayka D, Klei LR, Nemec AA, Bauer JA, Barchowsky A. 2005. Neovascularization and angiogenic gene expression following chronic arsenic exposure in mice. Cardiovasc Toxicol 5(1):29–41, PMID: 15738583, 10.1385/CT:5:1:029.

States JC, Srivastava S, Chen Y, Barchowsky A. 2009. Arsenic and cardiovascular disease. Toxicol Sci 107(2):312–323, PMID: 19015167, 10.1093/toxsci/kfn236.

Steinmaus C, Yuan Y, Kalman D, Rey OA, Skibola CF, Dauphine D, et al. 2010. Individual differences in arsenic metabolism and lung cancer in a case–control study in Cordoba, Argentina. Toxicol Appl Pharmacol 247(2):138–145, PMID: 20600216, 10.1016/j.taap.2010.06.006.

Straub AC, Stolz DB, Vin H, Ross MA, Soucy NV, Klei LR, et al. 2007. Low level arsenic promotes progressive inflammatory angiogenesis and liver blood vessel remodeling in mice. Toxicol Appl Pharmacol 222(3):327–336, PMID: 17123562, 10.1016/j.taap.2006.10.011.

Tarcan T, Siroky MB, Krane RJ, Azadzoi KM. 2000. Isoprostane 8-epi PGF2α, a product of oxidative stress, is synthesized in the bladder and causes detrusor smooth muscle contraction. Neurourol Urodyn 19(1):43–51, 10.1002/(SICI)1520-6777(2000)19:1<43::AID-NAU6>3.0.CO;2-C.

Tworoger S, Hankinson S. 2006. Use of biomarkers in epidemiologic studies: Minimizing the influence of measurement error in the study design and analysis. Cancer Causes Control 17(7):889–899, PMID: 16841256, 10.1007/s10552-006-0035-5.

USGS (U.S. Geological Survey). 2010. Assessment of arsenic concentrations in domestic well water, by town, in Maine, 2005–09. Scientific Investigations Report 2010-5199. [accessed 30 November 2017]

Wadham C, Albanese N, Roberts J, Wang L, Bagley CJ, Gamble JR, et al. 2004. High-density lipoproteins neutralize C-reactive protein proinflammatory activity. Circulation 109(17):2116–2122, PMID: 15078800, 10.1161/01.CIR.0000127419.45975.26.

WHO (World Health Organization). 2011. Guidelines for drinking-water quality, 4th edition. [accessed 30 November 2017]

Wu F, Jasmine F, Kibriya MG, Liu M, Wójcik O, Parvez F, et al. 2012. Association between arsenic exposure from drinking water and plasma levels of cardiovascular markers. Am J Epidemiol 175(12):1252–1261, PMID: 22534204, 10.1093/aje/kwr464.

Wu F, Molinaro P, Chen Y. 2014. Arsenic exposure and subclinical endpoints of cardiovascular disease. Curr Environ Health Rep 1(2):148–162, PMID: 25013752, 10.1007/s40572-014-0011-2.

Zheng L, Kuo C-C, Fadrowski J, Agnew J, Weaver VM, Navas-Acien A. 2014. Arsenic and chronic kidney disease: a systematic review. Curr Environ Health Rep 1(3):192–207, PMID: 25221743, 10.1007/s40572-014-0024-x.

Zheng LY, Umans JG, Yeh F, Francesconi KA, Goessler W, Silbergeld EK, et al. 2015. The association of urine arsenic with prevalent and incident chronic kidney disease: evidence from the Strong Heart Study. Epidemiology 26(4):601, PMID: 25929811, 10.1097/EDE.0000000000000313.

WP-Backgrounds Lite by InoPlugs Web Design and Juwelier Schönmann 1010 Wien